Novo Nordisk ADA +2.3%: CagriSema Data Back in Focus
Can Novo Nordisk ADA data finally give investors a reason to believe the GLP-1 leader can regain momentum? Maik Kemper Editor in Chief The conference highlights the strength…
Novo Nordisk FDA Compounding +4.8% Surge Shakes GLP‑1 Rivals
Will the Novo Nordisk FDA Compounding crackdown finally shut down GLP‑1 copycats and supercharge the branded obesity drug boom? Maik Kemper Editor in Chief When FDA‑approved drugs are…
Hims & Hers GLP-1 partnership sparks new weight-loss boom
Can the Hims & Hers GLP-1 partnership with Novo Nordisk turn telehealth weight loss into the company’s next major growth engine? Maik Kemper Editor in Chief When healthcare…
Hims & Hers insider transactions Warning as GLP-1 bets grow
Are Hims & Hers insider transactions hinting at caution just as the company doubles down on its high-stakes GLP-1 obesity strategy? Maik Kemper Editor-in-Chief Conclusion In conclusion, the…
Novo Nordisk GLP-1 competition Warning with new pill rival
Can Novo Nordisk defend its GLP-1 dominance as a potent oral rival emerges and a bold US telehealth deal reshapes distribution? How does Structure Therapeutics challenge Novo Nordisk?…
Novo Nordisk Hims partnership Boom: GLP‑1 market power shift
Can the Novo Nordisk Hims partnership turn a legal fight over compounded GLP‑1s into a powerful new growth channel for both sides? How does the Novo Nordisk Hims…